Riskpilot← Back to searchSign inGet full accessARXX THERAPEUTICS AS
ASActiveOrg 815295242Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20153 employees
Revenue 2024
NOK 5M
-31% vs 2023
EBITDA margin
-1334.9%
-21% vs 2023
Equity ratio
15.9%
Financial strength
Net profit 2024
NOK -67M
-18% vs 2023
| Revenue | NOK 5M | -31% |
| EBITDA | NOK -66,7M | -21% |
| Net profit | NOK -67M | -18% |
| Total assets | NOK 84,9M | +184% |
| Equity | NOK 13,5M | +33% |
| Employees | 3 | — |
Legal name
ARXX THERAPEUTICS AS
Org number
815295242
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. april 2015
Share capital
NOK 5 469 137
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Utvikle, markedsføre og selge legemidler.
Address
Gaustadalléen 21, 0349 Oslo
Phone
+4722958500
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 244 | 10 845 | 15 056 | 7 253 | 4 996 |
| Staff expenses | −4 527 | −6 914 | −9 857 | −15 478 | −15 224 |
| EBITDA | −13 516 | −33 308 | −87 484 | −55 066 | −66 685 |
| Depreciation & amort. | −0 | −184 | −224 | −240 | −96 |
| EBIT | −13 516 | −33 492 | −87 708 | −55 306 | −66 781 |
| Net financials | −65 | 219 | −358 | −1 629 | −200 |
| Profit before tax | −13 581 | −33 273 | −88 066 | −56 935 | −66 980 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −13 581 | −33 273 | −88 066 | −56 935 | −66 980 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 15 515 | 98 691 | 35 984 | 29 881 | 84 945 |
| Equity | 11 395 | 88 127 | 61 | 10 105 | 13 475 |
| Long-term debt | 0 | 0 | 19 132 | 0 | 0 |
| Short-term debt | 4 120 | 10 563 | 16 790 | 19 775 | 71 470 |
| Total debt | 4 120 | 10 563 | 35 923 | 19 775 | 71 470 |
EBITDA margin
-1334.9%
This company
15.8%
Market median
-8549% vs market
20202024
Equity ratio
15.9%
This company
38.2%
Market median
-58% vs market
20202024
Return on equity
-497.1%
This company
18.4%
Market median
-2802% vs market
20202024
Net profit margin
-1340.8%
This company
8.1%
Market median
-16653% vs market
20202024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20202024
Debt / equity
5.30×
This company
0.62×
Market median
-755% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
ØS Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
RI Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
KS Observer | Observer | 2023 – 2024 |
EP Observer | Observer | 2023 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2024 | |
| Chairman | 2025 | |
| Chairman | 2024 | |
| Former (5) | ||
| Chairman | 2023 – 2023 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2023 – 2024 | |
| Chairman | 2023 – 2024 | |
| Board of Directors | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 | |
| Company | 17.17% | 17.17% | 2022 | |
| Company | 17.17% | 17.17% | 2022 | |
| Company | 14.29% | 14.29% | 2022 | |
| Company | 7.23% | 7.23% | 2022 | |
| Company | 7.14% | 7.14% | 2022 | |
Andenes Investments Sl | Company | 5.75% | 5.75% | 2022 |
| Company | 5.09% | 5.09% | 2022 | |
| Company | 4.37% | 4.37% | 2022 | |
| Company | 4.04% | 4.04% | 2022 | |
| Company | 4.04% | 4.04% | 2022 | |
Tachris Ag | Company | 2.58% | 2.58% | 2022 |
| Company | 2.1% | 2.1% | 2022 | |
| Company | 2.02% | 2.02% | 2022 | |
| Company | 1.78% | 1.78% | 2022 | |
Mariam Grigorian | Company | 1.01% | 1.01% | 2022 |
Evgene Lukanidin | Company | 1.01% | 1.01% | 2022 |
Noune Ambartsoumian | Company | 1.01% | 1.01% | 2022 |
Jörg Klingelhöfer | Company | 1.01% | 1.01% | 2022 |
| Company | 1.01% | 1.01% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARXX THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øystein Soug | Chief Executive Officer | 0 companies |
| Rizwan Iqbal Hussain | Chief Executive Officer | 0 companies |
| Kjell Skappel | Observer | 0 companies |
| Erlend Petter Skagseth | Observer | 0 companies |
| Susanne Stuffers | Board of Directors | 0 companies |
| Christian Karl Kurt Schweiger | Chairman | 0 companies |
| Birgitte Gangmark Villmo | Board of Directors | 0 companies |
| Johannes Jacob Pieter Kastelein | Board of Directors | 0 companies |
| Yuri Khodjamirian | Board of Directors | 0 companies |
| Farzad Abdi-Dezfuli | Board of Directors | 0 companies |
| Jonas Hallén | Board of Directors | 0 companies |
| Sveinung Hole | Chairman | 0 companies |
| Mark William-Semrau Gaffney | Board of Directors | 0 companies |
| Antoine Boulanger Piette | Board of Directors | 0 companies |
| Berte Aagot Hedding Poulsson | Chairman | 0 companies |
| Marco Boorsma | Chairman | 0 companies |
| Kari Grønås | Board of Directors | 0 companies |